Nordic Nanovector ASA: Issuance of restricted stock unites (RSUs) to the new board member Joanna Horobin

Reference is made to the extraordinary general meeting of Nordic Nanovector ASA's (the "Company") on 12 October 2016 (the "EGM") where Joanna Horobin was elected a new board member.

At the ordinary general meeting of the Company the board of directors was authorised to issue restricted stock units ("RSUs") to the board members. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.20 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions.

Joanna Horobin has resolved to receive her full board remuneration, as determined by the Company's annual general meeting in 2016, in the form of RSU's and the board of directors has resolved to issue 2,678 RSU's to Joanna Horobin. The number of RSU's is calculated on the basis of a board remuneration of NOK 144,000 divided by the market price of the Company's shares calculated as the average share price for the 10 trading days prior to the EGM being NOK 53.77 per share. Joanna Horobin does not hold any other shares in the Company.

For further information, please contact:
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76

This information is subject to duty of disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act.



About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at